Switching from oral to transdermal rivastigmine can be safely achieved without titration, and may result in better GI tolerability,

Excerpt

Switching from oral to transdermal rivastigmine can be safely achieved without titration, and may result in better GI tolerability, according to a Spanish study.* Patients previously treated with rivastigmine capsules were randomised to either continue with the capsules (n = 51), or to switch to rivastigmine patch 9.5 mg/day either with (43) or without (48) titration for 3 months. No significant between-group differences in adverse events of any nature were observed over the study period. GI adverse events (diarrhoea, nausea or vomiting) were reported in 6.1% of rivastigmine capsule recipients, and in 4.7% and 4.3% of the rivastigmine patch titration and no titration groups, respectively. …